Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Window-of-opportunity olaparib with or without durvalumab before primary debulking surgery in high-grade epithelial ovarian cancer
2020-005101-12Phase 2Active
- Sponsor
- AGO Research
- Start
- Jun 2021
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of olaparib and durvalumab in epithelial ovarian cancer (EOC) and ovarian cancer (2 cohorts), sponsored by AGO Research. Primary endpoint: Feasibility of window-of-opportunity administration. Started Jun 2021; status: active.
02
Drugs
olaparibdurvalumab
03
Conditions
epithelial ovarian cancer (EOC)ovarian cancer
Beyond the preview
Go deeper on 2020-005101-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005101-12.